RUBY - Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer Last updated on Feb 3, 2025 Previous NRG GY018: Pembrolizumab in Advanced Endometrial Cancer Next PORTEC 2: Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk
